BIO 2009

[ May 18-21, 2009 ]
Atlanta, USA
DNDi and iOWH hoeld panel sessions at BIO 2009.

World Leish 4

[February 3-7, 2009]
Lucknow, India
Every 4 years, leishmaniasis experts gather together from around the world. During World Leish 4, DNDi held 2 symposia on “partnering along the path to deliver better treatments”.

3rd Annual Meeting of PASN – Tokyo

[ June 2008 ]

Tokyo, Japan
Leading researchers from research institutes in Asia, DNDi, and MMV met from 9th-11th June to share their vision to make Asia a major player in drug development for the neglected diseases, utilizing local natural resources. This meeting of PAN4ND was co-hosted by DNDi and the Kitasato Institute.

Stakeholder Meeting

[ June 26, 2008 ]
New York, USA
DNDi’s First Stakeholders’ meeting took place on 26th June in New York and brought together 150 scientists, researchers, academics, and global health leaders from 25 countries to discuss how international research partnerships can best develop and deliver new lifesaving  drugs for neglected diseases.

ASMQ Launch

[ April 2008 ]
Rio de Janeiro, Brazil
Farmanguinhos/Fiocruz and DNDi launched ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), now registered in Brazil. Developed and delivered by a worldwide collaboration of public partners, ASMQ will soon be available throughout Latin American and Southeast Asia.

10th Leishmaniasis East Africa Platform (LEAP) – Sudan

[ February 2008 ]
The 10th Leishmaniasis East Africa Platform (LEAP) meeting took place in Khartoum, Sudan. A solid clinical trial network is being built, thanks to the serious commitment of all members. Capacity building is still ongoing, with one site in Kenya to be built and another in Uganda to be strengthened. In May 2008, DNDi and its partners inaugurated a new treatment centre in Gondar, Ethiopia, with a 24 bed capacity.

DNDi Symposium on ACT: 56th American Society of Tropical Medicine and Hygiene (ASTMH 2007)

[ November 2007 ]
Philadelphia, USA
Sanofi-aventis and DNDi held a symposium on the implementation of a new artemisinin combination therapy (ACT) in African endemic countries. Over 120 attendees from NGOs, academia, and the pharmaceutical sector heard presentations by FACT project partners on ASAQ and ASMQ. In addition, DNDi also presented the ethical considerations of malaria field studies, and screening of natural products against infectious disease pathogens.

Scientific Symposium on Visceral Leishmaniasis (VL)

[ September 2007 ]
London, UK
DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.

ASAQ Launch

[ March 2007 ]
Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use, accessible as a non patented drug, and available at an affordable price.

Second DNDi Africa Meeting

[ September 2006 ]
Nairobi, Kenya
Over 200 African scientists from 34 countries met in Nairobi, Kenya, 19-23 September at an international conference organised by the Drugs for Neglected Diseases initiative (DNDi), to explore developing greater regional research partnerships to combat the most neglected diseases, such as sleeping sickness, kala azar and malaria.


 6-11 August 2006 ]
Glasgow, Scotland

11th International Congress of Parasitology.